Overview
The cognitive and neuro-research peptides here are studied for neurotrophic and neuromodulatory signaling, largely in preclinical and early clinical literature. Evidence depth varies widely across the group, so this guide states the strength of the published record for each compound plainly rather than implying a uniform effect.
A melanocortin receptor agonist (bremelanotide) studied for centrally-mediated signaling.
Evidence at a glance: Includes human-trial data
The cited record for this compound includes human-trial data. Each claim below still states its study type and population, so the scope of that evidence stays explicit.
Molecular identity
- Molecular formula
- C50H68N14O10
- Molecular weight
- 1025.2 g/mol
- CAS number
- 189691-06-3
- Amino acids
- 7
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 99.1%
Researched mechanism
Agonist at melanocortin receptors (notably MC4R) acting via central pathways.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
What the published research shows
Centrally-mediated effects characterized in controlled human studies.
Every citation states its study type and population, so preclinical data is never presented as human-efficacy evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| MT-2 | Receptor profile | MT-2 is a broader melanocortin agonist studied for pigmentation. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 10 mg | 2 mL | 5 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Common questions
How does it differ from MT-2?+
Different melanocortin receptor emphasis; see the comparison note. Both are RUO research materials.
